Zydus Cadila gets USFDA nod for Tizanidine tablets
New Delhi: Cadila Healthcare said its group firm Zydus Cadila has received final approval from the US health regulator for its generic version of Tizanidine tablets used for the treatment of muscle spasms.
The approval by the US Food and Drug Administration (USFDA) is for multiple strengths of 2 mg and 4 mg, the company said in a BSE filing.
The tablets will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad, the company added.
Tizanidine tablets are used to treat muscle spasms caused by certain conditions such as multiple sclerosis, spinal cord injury, it said.
The group has more than 180 approvals with over 320 abbreviated new drug approvals (ANDAs) filed since 2003-04, the company said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd